Michelle Orr, MD
Endocrinology, Diabetes & Metabolism · Kansas City, MONPI 1598769291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations.
Across 314 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$604
- Lilly USA, LLC$600
- Boehringer Ingelheim$596
- Abbott$546
- AstraZeneca$399
- Amgen$305
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,355100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $604 |
| Lilly USA, LLC | 34 | $600 |
| Boehringer Ingelheim | 47 | $596 |
| Abbott | 30 | $546 |
| AstraZeneca(2 entities) | 23 | $399 |
| Amgen(2 entities) | 16 | $305 |
| Sanofi-aventis U.S. LLC | 17 | $257 |
| Radius Health, Inc. | 8 | $246 |
| Amarin Pharma, Inc. | 15 | $222 |
| Dexcom, Inc. | 10 | $213 |
| Cequr Corporation | 3 | $127 |
| Insulet Corporation | 6 | $110 |
| Ascensia Diabetes Care US Inc. | 5 | $108 |
| Pfizer | 7 | $104 |
| AbbVie | 6 | $89 |
| Neurocrine Biosciences, Inc. | 4 | $85 |
| Corcept Therapeutics | 4 | $74 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| Merck | 4 | $60 |
| Ascendis Pharma Endocrinology Inc | 2 | $57 |
| Antares Pharma, Inc. | 4 | $55 |
| Abiomed | 2 | $49 |
| IBSA Pharma Inc. | 3 | $45 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| Johnson & Johnson | 3 | $40 |
| Mannkind Corporation | 2 | $40 |
| Astellas Pharma US Inc | 2 | $39 |
| BD | 2 | $34 |
| Medtronic(2 entities) | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Embecta Corp. | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Bayer | 1 | $16 |
| Novartis | 1 | $15 |
How this compares
$5,378 in reported general payments places this provider in the 70th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 274 | $307,377 |
| OzempicSemaglutide | 133 | $191,084 |
| TrulicityDulaglutide | 35 | $54,230 |
| MounjaroTirzepatide | 37 | $50,737 |
| FarxigaDapagliflozin Propanediol | 49 | $46,218 |
| ProliaDenosumab | 23 | $38,807 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $34,910 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $23,272 |
| JanuviaSitagliptin Phosphate | 25 | $22,923 |
| Novolog FlexpenInsulin Aspart | 76 | $20,770 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $19,215 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 121 | $17,680 |
| Humalog Kwikpen U-100Insulin Lispro | 58 | $17,528 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $15,786 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $14,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $596 | $307,377274 claims |
| Novo NordiskOzempic | $604 | $191,084133 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $600 | $104,96772 claims |
| AstraZenecaFarxiga | $399 | $46,21849 claims |
| AmgenProlia | $305 | $38,80723 claims |
| MerckJanuvia | $60 | $22,92325 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $5,602578 claims |
| AbbVieSynthroid | $89 | $2,65851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Kansas City
- Rajib BhattacharyaKansas City$49K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.